Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 3Neoplasm Metastasis 2Solid Tumors 1Resectable Non-Small Cell Lung Cancer 1Brain Neoplasms 1

Interventions

atezolizumab 3Docetaxel 3pembrolizumab 2olaparib 2lenvatinib 2Leucovorin 2Irinotecan 2Immune Checkpoint Inhibitors 2Fluorouracil 2Filgrastim 2Capecitabine 2zolbetuximab 1tomivosertib 1spartalizumab 1somatostatin receptor 2 1pralsetinib 1pegylated granulocyte colony-stimulating factor 1necitumumab 1motesanib diphosphate 1ipatasertib 1inavolisib 1entrectinib 1ensartinib 1dapagliflozin 1cobimetinib 1cemiplimab 1cat's claw extract 1balugrastim 1anlotinib 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Solid Tumors × adagrasib × Clear all
NCT07415031 2026-05-15

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Mirati Therapeutics Inc.

Phase 2 Recruiting
170 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡